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Lung perfusion scintigraphy 
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lung transplantation
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Because chronic lung allograft dysfunction (cLAD) develops predominantly on one side after bilateral 
living‑donor lobar lung transplantation (LDLLt), lung perfusion scintigraphy (Q‑scinti) was expected 
to show a perfusion shift to the contralateral unaffected lung with the development of CLAD. Our 
study examined the potential usefulness of Q-scinti in the diagnosis of CLAD after bilateral LDLLT. We 
conducted a single-center retrospective cohort study of 58 recipients of bilateral LDLLT. The unilateral 
shift values on Q-scinti were calculated and compared between the CLAD group (N = 27) and the non-
CLAD group (N = 31) from 5 years before to 5 years after the diagnosis of CLAD. The unilateral shift 
values in Q-scinti were significantly higher in the CLAD group than in the non-CLAD group from 5 years 
before the diagnosis of CLAD to 5 years after the diagnosis (P < 0.05). The unilateral shift values in 
Q-scinti were significantly correlated with the percent baseline values of the forced expiratory volume 
in 1 s (P = 0.0037), the total lung capacity (P = 0.0028), and the forced vital capacity (P = 0.00024) at 
the diagnosis of CLAD. In patients developing unilateral CLAD after bilateral LDLLT, Q-scinti showed 
a unilateral perfusion shift to the contralateral unaffected lung. Thus, Q-scinti appears to have the 
potential to predict unilateral CLAD after bilateral LDLLT.
Recipients of lung transplantation (LT) still have a worse long-term survival than heart, liver, or kidney 
 recipients1–3. The recipients of LT mainly succumb to chronic lung allograft dysfunction (CLAD)1–3 in the long 
term after both cadaveric LT and living-donor lobar lung transplantation (LDLLT)4. For the diagnosis of CLAD 
after LDLLT, lung ventilation scintigraphy was previously shown to be beneficial using 133Xe washout  imaging5. 
However, because 133Xe was discontinued in 2016 and is no longer available in the world, a new diagnostic 
approach has been sought for CLAD after LDLLT.
Lung perfusion scintigraphy (Q-scinti) has been shown to be valuable for the diagnosis of CLAD after single 
LT, as  follows6, 7. After single LT, Q-scinti normally shows a lung perfusion shift to the transplanted lung, rather 
than to the native lung, because of the lower vascular resistance of the graft; however, in patients developing 
CLAD after single LT, the perfusion decreases in the lung affected by CLAD, with a perfusion shift toward the 
native  lung6, 7.
Interestingly, even in patients undergoing bilateral LDLLT, CLAD predominantly develops in a unilateral 
lung because in bilateral LDLLT, the lobar lung transplants are obtained from two different donors with different 
immunological  backgrounds4, 8. Therefore, we considered that in patients developing CLAD after bilateral LDLLT, 
Q-scinti could show a decrease in the perfusion of the lung affected by CLAD and a perfusion shift toward the 
contralateral unaffected lung. Our study evaluated the usefulness of Q-scinti in the diagnosis of CLAD, which 
is predominantly unilateral, in patients who have undergone bilateral LDLLT.
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Results
Table 1 shows the patient characteristics, and a schematic diagram of this study cohort is shown in Fig. 1. The 
risk factors for  CLAD9 did not differ between the two groups, including human leukocyte antigen mismatches, 
cytomegalovirus mismatches, the incidence of primary graft dysfunction, the incidence of acute rejection, and 
the incidence of gastroesophageal reflux disease. The median observation period after bilateral LDLLT in the 
CLAD group (median, 3,733 days; range 679–6,298 days) was similar to that in the non-CLAD group (median, 
3,907 days; range 722–5,931 days), and the median time to the onset of CLAD after LDLLT was 2,176 days 
(326–4,763 days) in the CLAD group.
As shown in Fig. 2, in the recipients with unilateral CLAD after bilateral LDLLT, Q-scinti demonstrated 
a perfusion shift towards the contralateral unaffected lung. Unsurprisingly, the percent baseline value of the 
forced expiratory volume in 1 s (FEV1) in the CLAD group was significantly lower than that in the non-CLAD 
group at and after the diagnosis of CLAD. Notably, the unilateral shift values in Q-scinti, as shown in Fig. 3, were 
significantly higher in the CLAD group than in the non-CLAD group from even 5 years before the diagnosis of 
CLAD to 5 years after the diagnosis of CLAD (Fig. 4A). Furthermore, in the CLAD group, there was no signifi-
cant difference in the unilateral shift value in Q-scinti between the group with bronchiolitis obliterans syndrome 
(BOS) and restrictive allograft syndrome (RAS), and the unilateral shift values in Q-scinti in both the CLAD 
subgroups with BOS and RAS were significantly higher than the value in the non-CLAD group from the time of 
the diagnosis of CLAD to 5 years after the diagnosis (Fig. 4B). A receiver operating characteristic curve (ROC) 
analysis to determine the performance of the unilateral shift value in Q-scinti for the diagnosis of CLAD yielded 
an area under the curve of 0.79, with a sensitivity of 100% and a specificity of 54% at a cutoff value of 8.55% 
(Fig. 5). Furthermore, at the diagnosis of CLAD after bilateral LDLLT, the unilateral shift values in Q-scinti were 
moderately but significantly correlated with the percent baseline values of FEV1, the total lung capacity (TLC), 
and the forced vital capacity (FVC) (FEV1, P = 0.0037, r = − 0.43; TLC, P = 0.0028, r = − 0.47; FVC, P = 0.00024, 
r = − 0.53), but not the 6-min walk distance (P = 0.097, r = − 0.27) (Fig. 6). The prevalence of subsequent CLAD 
was significantly higher in the patients with a unilateral shift value in Q-scinti ≥ 1% at 1 year after LDLLT than 
in those with a unilateral shift value in Q-scinti < 1% (Fig. 7).
Table 1.  Patient characteristics. Data are presented as n, median (range) or n (%). CMV cytomegalovirus, 
GERD gastroesophageal reflux disease, HLA human leukocyte antigen, PGD primary graft dysfunction.
Non-CLAD (N = 31) CLAD (N = 27) P value
Preoperative variables
 Age (years), median (range) 32 (7–55) 31 (8–64) 0.69
 Gender
  Male 6 (19.4%) 6 (22.2%) 0.78
  Female 25 (80.6%) 21 (77.8%)
 Body mass index, median (range) 16.7 (10.8–26.6) 18.5 (10.5–29.0) 0.044
 Diagnoses
  Interstitial lung disease 11 (35.5%) 9 (33.3%) 0.18
  Pulmonary hypertension 9 (29.0%) 9 (33.3%)
  Pulmonary graft-versus-host disease 6 (19.4%) 1 (3.7%)
  Emphysema 0 (0%) 1 (3.7%)
  Bronchiectasis 0 (0%) 3 (11.1%)
  Other diseases 5 (16.1%) 4 (14.8%)
 Preoperative use of glucocorticoids, yes 15 (48.4%) 9 (33.3%) 0.29
 Preoperative diabetes mellitus, yes 2 (6.5%) 1 (3.7%) 1
 Lung allocation score, median (range) 46.0 (34.3–89.5) 40.8 (33.1–86.0) 0.068
 CMV mismatch (recipient negative/donor positive), yes 6 (19.4%) 1 (3.7%) 0.11
 Total number of HLA-A, HLA-B and HLA-DR mismatches, median (range) 5.5 (2–11) 7 (3–10) 0.078
Intraoperative variables
 Operative time (min), median (range) 444 (307–785) 477 (335–615) 0.74
 Ischemic time (min), median (range) 163 (74–221) 169 (84–243) 0.29
 Cardiopulmonary bypass use, yes 31 (100%) 27 (100%) 1
Postoperative variables
 Maximum grade of PGD (0–72 h), median (range) 1 (0–2) 0 (0–2) 0.50
 Intravenous administration of calcineurin inhibitor, yes 9 (29.0%) 3 (11.1%) 0.12
 Basiliximab usage, yes 8 (25.8%) 4 (14.8%) 0.35
 Acute rejection, yes 17 (54.8%) 16 (59.3%) 0.80
 Antibody-mediated rejection, yes 4 (12.9%) 1 (3.7%) 0.36
 Postoperative GERD, yes 1 (3.2%) 1 (3.7%) 1
 Time since transplant to follow-up (day), median (range) 3,907 (722–5,931) 3,733 (679–6,298) 0.96
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Discussion
In this study, after bilateral LDLLT, the unilateral shift value in Q-scinti was significantly higher in patients 
with CLAD than in patients without CLAD from 5 before to 5 years after the diagnosis of CLAD. Moreover, the 
unilateral shift values in Q-scinti did not differ across subgroups (BOS and RAS) throughout the study period, 
and both the BOS and RAS subgroups showed significantly increased unilateral shift values in Q-scinti at CLAD 
diagnosis, compared with those in the non-CLAD patients. Furthermore, the unilateral shift values in Q-scinti 
were significantly correlated with the percent baseline values of FEV1, TLC and FVC at the diagnosis of CLAD. 
Our results suggest that the unilateral perfusion shift to the unaffected lung in Q-scinti could predict the devel-
opment of unilateral CLAD after bilateral LDLLT. To the best of our knowledge, this is the first report to focus 
on Q-scinti as a potential diagnostic tool for CLAD after bilateral LDLLT.
CLAD after bilateral LDLLT develops  unilaterally4, 8 because the transplanted lung lobes in bilateral LDLLT 
originate from two different donors with different immunological backgrounds. The diagnosis of CLAD is 
based on pulmonary function  tests10, 11. However, after bilateral LDLLT, the unaffected contralateral lung might 
mask the functional decline and delay the diagnosis of CLAD. Until 2016, ventilation scintigraphy with 133Xe 
washout imaging was used for the diagnosis of unilateral CLAD after bilateral  LDLLT5, but the use of 133Xe was 
discontinued. As an alternative diagnostic tool, inspiratory and expiratory computed tomography volumetry has 
been used to detect unilateral CLAD after bilateral LDLLT, but this volumetric method rarely allows the early 
detection of  CLAD12. By contrast, our study showed that the perfusion shift in Q-scinti predicts the development 
of unilateral CLAD from 5 years before the diagnosis of CLAD after bilateral LDLLT. Moreover, the perfusion 
shift in Q-scinti was correlated with the postoperative changes in FEV1, TLC and FVC at the onset of CLAD. 
Even in patients with low perfusion shift percentages at 1 year after LDLLT, the prevalence of subsequent CLAD 
was significantly higher than in those without a perfusion shift. Therefore, Q-scinti appears to have excellent 
potential for the early screening of patients at risk for the development of unilateral CLAD after bilateral LDLLT. 
As LDLLT is currently performed exclusively in Japan, this diagnostic approach might be useful only in this 
country, but this approach could potentially lead to further examination and enhanced immunosuppression for 
the early diagnosis and prompt treatment of unilateral CLAD in these patients.
Theoretically, the distribution of the lung perfusion after bilateral LDLLT depends on the lung volume of 
the transplanted lung lobes, since the lung grafts from healthy living donors have normal vascular resistance in 
intact vascular beds. When the graft function deteriorates after bilateral LDLLT, the lung perfusion shifts toward 
the contralateral unaffected lung because of the relatively lower vascular resistance in that lung. In this study, a 
cutoff value of 8.55% for unilateral shift was found to have a sensitivity of 100% and a specificity of 54% for the 
diagnosis of CLAD at the time of CLAD diagnosis after bilateral LDLLT. Furthermore, the lung perfusion shift 
to the unaffected lung in Q-scinti became more significant when the FEV1 started declining in patients with 
CLAD. These findings indicate that in patients developing CLAD after bilateral LDLLT, the decrease in perfusion 
of the affected lung might precede the changes in airway compliance, as described for single  LT7. This result is 
consistent with former animal experiments, demonstrating that a decrease in lung perfusion leads to a decrease 
in pulmonary  function13. The decrease in the lung perfusion in the affected lung with CLAD might be attribut-
able to the inflammatory process of CLAD or graft  vasculopathy14. Further study is required to elucidate the 
mechanisms of this decrease in lung perfusion and how it could lead to a decline in FEV1 in patients developing 
CLAD after bilateral LDLLT.
Figure 1.  Flow-chart of the study cohort. Bilateral living-donor lobar lung transplantation (LDLLT) was 
performed in 65 patients during the study period. Seven patients, including five patients who died within 
1 year of the LDLLT and two pediatric patients in whom lung perfusion scintigraphy (Q-scinti) could not be 
performed, were excluded from this study. Of the remaining 58 patients, 27 patients who developed chronic 
lung allograft dysfunction (CLAD) were designated as the CLAD group (N = 27), and 31 patients who did not 
develop CLAD were designated as the non-CLAD group (N = 31).
4Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:10595  | https://doi.org/10.1038/s41598-020-67433-4
www.nature.com/scientificreports/
Figure 2.  Representative course of unilateral chronic lung allograft dysfunction (CLAD) after bilateral 
living-donor lobar lung transplantation (LDLLT). Lung perfusion scintigraphy demonstrated a perfusion 
shift to the contralateral unaffected lung in the patient with unilateral CLAD after bilateral LDLLT, which was 
also associated with a decline in the forced expiratory volume in 1 s (FEV1) associated with CLAD. The lung 
ventilation scintigraphy showed that the washout of radionuclide tracer became slower, indicating air trapping 
in the lung affected with unilateral CLAD.
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Figure 3.  Formula for calculating the unilateral shift value in lung perfusion scintigraphy (Q-scinti). For 
example, the perfusion rate of the right lung was 60% at 3 months after a bilateral living-donor lobar lung 
transplantation (LDLLT), which was defined as the initial value. Then, the perfusion rate of the right lung 
increased to 80% because of chronic lung allograft dysfunction (CLAD) of the left lung at the follow-up 
conducted one year after bilateral LDLLT; this value was defined as the comparison value. For this case, the 
unilateral shift value in Q-scinti was calculated as 20% according to the equation. The lung images in the figure 
were created by Hidetoshi Yanase, who provided permission for their publication.
Figure 4.  Postoperative changes in the unilateral shift values in lung perfusion scintigraphy (Q-scinti) after 
bilateral living-donor lobar lung transplantation (LDLLT). (A) The unilateral shift values in Q-scinti were 
significantly higher in the chronic lung allograft dysfunction (CLAD) group than in the non-CLAD group from 
5 years before the diagnosis of CLAD to 5 years after the diagnosis of CLAD. (B) In the CLAD group, there was 
no significant difference in the unilateral shift value in Q-scinti between the group with bronchiolitis obliterans 
syndrome (BOS) and that with restrictive allograft syndrome (RAS), and the unilateral shift values in Q-scinti in 
both of the CLAD subgroups, BOS and RAS, were significantly higher than the value in the non-CLAD group 
from the time of CLAD diagnosis until 5 years after diagnosis. (C) The P value is for the comparison between 
groups in each year before and after the onset of CLAD.
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Regarding radiation exposure, the dose during Q-scinti was 1.48–3.00 mGy/37 MBq, and the required dose 
was relatively low, at 0.8 mSV; in contrast, the radiation dose for chest X-ray is 0.2 mSV and that for contrast-
enhanced computed tomography ranges from 1.6 to 8.3 mSV6, 7. In general, Q-scinti is used for the diagnosis 
of pulmonary thrombosis, even in pregnant women with acute pulmonary  thrombosis6, 7. Given these factors, 
Q-scinti is considered to be a potentially acceptable diagnostic tool for the long-term follow-up of patients after 
bilateral LDLLT.
Figure 5.  Receiver operating characteristic curve analysis to determine the performance of the unilateral shift 
value in lung perfusion scintigraphy for the diagnosis of chronic lung allograft dysfunction. The analysis yielded 
an area under the curve of 0.79, with a sensitivity of 100% and a specificity of 54% at a cutoff value of 8.55%.
Figure 6.  Correlation between the unilateral shift values in lung perfusion scintigraphy (Q-scinti) and (A) the 
percent baseline values of the forced expiratory volume in 1 s (FEV1), (B) the total lung capacity (TLC), (C) 
the forced vital capacity (FVC), and (D) the 6-min walk distance (6-MWD). There was a significant correlation 
between the unilateral shift values in Q-scinti and the percent baseline values of the FEV1, TLC and FVC, 
but not the 6-MWD, at the time of the diagnosis of chronic lung allograft dysfunction (CLAD) after bilateral 
living-donor lobar lung transplantation (LDLLT), as determined using the Pearson product-moment correlation 
coefficient (FEV1, P = 0.0037, r = − 0.43; TLC, P = 0.0028, r = − 0.47; FVC, P = 0.00024, r = − 0.53; 6-MWD, 
P = 0.097, r = − 0.27).
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The present study had several limitations. First, this was a retrospective study conducted at a single transplant 
institution. Second, the number of LDLLT recipients and CLAD patients was relatively small in our study. Third, 
in some cases, the follow-up period was of intermediate duration, and longer follow-up periods are needed 
to validate the prognostic impact of CLAD, although the follow-up period was more than one year in all the 
patients. Fourth, because we set the unilateral shift values in Q-scinti at 6 years after LDLLT as the control value 
in the non-CLAD group, the time point of the unilateral shift values in Q-scinti differed between the CLAD 
and non-CLAD groups. However, given the fact that LDLLT is currently performed exclusively in Japan, our 
study provides practical information for the long-term follow-up and diagnosis of CLAD after bilateral LDLLT.
In conclusion, after bilateral LDLLT, the unilateral perfusion shift to the contralateral, unaffected lung in 
Q-scinti was associated with the development of CLAD and increased after the onset of CLAD. Moreover, the 
lung perfusion shift in Q-scinti was associated with declines in the FEV1, TLC and FVC at the time of CLAD 
diagnosis after bilateral LDLLT. Based on our findings, we concluded that Q-scinti had the potential to predict 
unilateral CLAD after bilateral LDLLT.
Methods
Patients. This was a single-center retrospective cohort study in which 65 patients who had undergone bilat-
eral LDLLT at Okayama University Hospital between October 1998 and October 2014 were initially enrolled. 
Seven patients, including two pediatric patients in whom Q-scinti could not be performed and five patients 
who died within 1 year of the LDLLT, were excluded from this study. No organs were procured from prisoners 
in this study. Of the remaining 58 patients, 27 patients who developed CLAD were designated as the CLAD 
group (N = 27), and 31 patients who did not develop CLAD were designated as the non-CLAD group (N = 31). 
The CLAD group was divided into the BOS group (N = 14) and the RAS group (N = 13) according to CLAD 
phenotype.
The triple immunosuppressive therapy consisted of calcineurin inhibitors including tacrolimus or cyclo-
sporine, mycophenolate mofetil or azathioprine, and glucocorticoid after LDLLT. Calcineurin inhibitor was 
enterically administered through a nasogastric tube for patients treated between 1998 and 2010 or was intra-
venously administered for patients treated between 2011 and 2014, followed by oral administration early after 
 LDLLT15. Basiliximab was administered to patients at risk of developing renal dysfunction.
Pulmonary function testing and Q-scinti were performed at 3, 6 and 12 months after LT and every year there-
after. Until 2016, lung ventilation scintigraphy was performed at the same time as Q-scinti to diagnose CLAD 
using 133Xe washout  imaging5. According to the classification system proposed by the International Society of 
Heart and Lung Transplantation (ISHLT)10, 11, obstructive CLAD or BOS was defined as an irreversible decline 
of the FEV1 to < 80% of the baseline value, and restrictive CLAD or RAS was defined as an irreversible decline 
Figure 7.  Prevalence of subsequent CLAD according to the unilateral shift values in lung perfusion 
scintigraphy (Q-scinti) at 1 year after bilateral living-donor lobar lung transplantation (LDLLT). The prevalence 
of subsequent CLAD was significantly higher in the patients with a unilateral shift value in Q-scinti ≥ 1% at 
1 year after LDLLT than in those with a unilateral shift value in Q-scinti < 1% (P = 0.00048). Applying a cut-off 
value of 2% or 3% of the unilateral shift value in Q-scinti also resulted in significant differences in the prevalence 
of subsequent CLAD.
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of both the FEV1 to < 80% and the total lung capacity (TLC) to < 90% of the values measured at  baseline10, 11. 
The baseline values of the FEV1 and TLC were calculated as the average of the two best values obtained at least 
3 weeks apart.
Q-scinti was performed after the intravenous administration of 185 MBq of 99c-macroaggregated albumin 
(= 99mTc-MAA, Techne MAA kit, FUJIFILM, JAPAN) with the patient in a supine position. Images in the ante-
rior and posterior oblique views were obtained by collecting 7,000,000 counts per view on a single-head gamma 
camera (GCA901A/HG; Toshiba Medical) using a single photon emission computed tomography system (Symbia 
T16; Siemens Medical Solutions, USA) equipped with a parallel-hole collimator. Images obtained in the posterior 
view were used to calculate the relative perfusion.
For the differential diagnosis of CLAD, a blood examination, plain chest X-ray, computed tomography of the 
chest, 6-min walk test, electrocardiography, and echocardiography were also performed at the same time as the 
pulmonary function testing and Q-scinti. Transbronchial biopsy was not performed to diagnose CLAD after 
LDLLT to avoid unexpected bleeding or pneumothorax from the small lobar  grafts16. The study protocol (No. 
1901-026) was approved, and individual written informed consent was waived by the institutional review board 
of Okayama University Hospital. All the methods were performed in accordance with the relevant guidelines 
and regulations.
Evaluation of lung perfusion scintigraphy. The unilateral shift values of lung perfusion in Q-scinti 
were calculated using the following equation (Fig. 3):
where “Initial value” is the perfusion rate of the right lung (%) in Q-scinti within 6 months after bilateral LDLLT, 
and “Comparison value” perfusion rate of the right lung (%) in Q-scinti at the follow-up conducted one year 
after bilateral LDLLT.
The unilateral shift values in Q-scinti were compared between the CLAD group and the non-CLAD group 
from 5 before to 5 years after the diagnosis of CLAD. In the CLAD group, the median time to the onset of CLAD 
after bilateral LDLLT was 2,176 days (5.96 years), or nearly 6 years after LDLLT; thus, the unilateral shift value in 
Q-scinti at 6 years after bilateral LDLLT was designated as the control value in the non-CLAD group. In addition, 
in the CLAD group, a subgroup analysis was performed to compare the unilateral shift values in Q-scinti between 
the patients with BOS and those with RAS. To assess the potential for the early screening of CLAD, the prevalence 
of subsequent CLAD was examined according to the unilateral shift values in Q-scinti at 1 year after LDLLT.
Statistical analysis. All the statistical analyses were performed using the GraphPad Prism 7.04 software 
(San Diego, CA, USA). The Student t-test was used to compare the changes in the unilateral shift values in 
Q-scinti between the CLAD and non-CLAD groups. The Bonferroni correction was used for multiple compari-
sons between two groups among the non-CLAD, BOS and RAS groups, and a one-way ANOVA was used for a 
three-factor comparison analysis among the non-CLAD, BOS and RAS groups. Missing data were not replaced. 
Differences in the patient characteristics between two groups were tested using the Mann–Whitney U test for 
continuous variables and the Pearson chi-square test for categorical variables. Differences were considered sig-
nificant at P < 0.05. An ROC analysis was performed to determine the optimal cutoff value for the unilateral 
shift value in Q-scinti between two groups. The Pearson product-moment correlation coefficient was calculated 
between the unilateral shift values in Q-scinti and the percent baseline values of FEV1, TLC, FVC, or the 6-min 
walk distance at the diagnosis of CLAD after bilateral LDLLT.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author upon reasonable request.
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